Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00698061 |
Subjects who had not responded to previous hepatitis B vaccination were vaccinated with either the adjuvanted HBV-MPL vaccine or Engerix™-B vaccine according to a three-dose vaccination schedule (0, 1, 2 months) and boosted at Month 12 as per their group allocation. The immunogenicity and safety of the HBV-MPL vaccine were compared with the control vaccine, Engerix™-B.
Condition | Intervention | Phase |
---|---|---|
Hepatitis B |
Biological: HBV-MPL vaccine 208129 Biological: Engerix™-B |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind (Subject), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Study to Compare the Immunogenicity and Safety of GSK Biologicals Adjuvanted HBV Vaccine to Engerix™-B, in a Non-Responder Population ≥ 15 Years of Age, When Administered Intramuscularly, According to a 0, 1, 2, 12 Month Schedule |
Enrollment: | 145 |
Study Start Date: | December 1999 |
Primary Completion Date: | May 2001 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Group A: Experimental |
Biological: HBV-MPL vaccine 208129
3-dose primary vaccination and booster vaccination by intramuscular injection
|
Group B: Active Comparator |
Biological: Engerix™-B
3-dose primary vaccination and booster vaccination by intramuscular injection
|
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Ages Eligible for Study: | 15 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
At study entry:
Before booster dose at month 12:
Exclusion Criteria:
Belgium | |
GSK Clinical Trials Call Center | |
Brussels, Belgium | |
Spain | |
GSK Clinical Trials Call Center | |
Madrid, Spain |
Study Director: | Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Isabelle Harpigny ) |
Study ID Numbers: | 208129/033, 208129/038 |
Study First Received: | June 11, 2008 |
Last Updated: | June 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00698061 History of Changes |
Health Authority: | Spain: Ministry of Health; Belgium: Institutional Review Board |
Adjuvanted vaccine Hepatitis B |
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases |
Hepatitis B Hepatitis, Viral, Human DNA Virus Infections |
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases |
Hepatitis B Hepatitis, Viral, Human DNA Virus Infections Hepadnaviridae Infections |